Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and kidney- protective effects.
This article was originally published on MedicalXpress.com
Sotagliflozin outperforms dapagliflozin for reducing salt- sensitive hypertension and kidney injury in rats
You may also be interested in:
The Latest
The Key to a Strong Relationship? Communication
Effective communication is the foundation of any strong, healthy relationship. This article will explore the key elements required to build better communication between partners. We’ll cover the importance of active listening, using empathy and understanding […]
The Latest
Will a nutritional supplement help you run better?
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
Food
Transform Your Kitchen: Mastering Allergy-Safe Cooking Through Ingenious Ingredient Swaps
By Daniel Zane Bryant, author of “Living with Food Allergies: A Complete Lifestyle Guide” (available on Amazon at https://www.amazon.com/dp/B0G2BcGB2K) Navigating food allergies might initially feel overwhelming, yet it presents an exciting opportunity to reimagine familiar […]
Read More:
-
When ophthalmologist Emily Cole, MD, steps into the neonatal intensive care unit (NICU) at Children’s Hospital Colorado to evaluate an infant’s eyes for a disease [...]
-
Prenatal exposure to metal mixtures is associated with an increased risk for allergic symptoms in childhood, according to a study published in the Dec. 1 [...]
-
A new study in JAMA Network Open describes patterns of telehealth use before and during the COVID-19 pandemic among children in the Bronx.This article was [...]
